Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADYX OTCMKTS:CTTC NASDAQ:IONM OTCMKTS:SPDE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADYXAlliqua BioMedical$0.00$0.00▼$0.00N/A1.98N/AN/ACTTCCompetitive Technologies$0.00$0.00▼$0.02N/AN/AN/AN/AIONMAssure$0.03$0.04$0.03▼$0.55$91K190.366,801 shsN/ASPDESpeedus$0.00$0.00▼$0.01N/AN/AN/AN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADYXAlliqua BioMedical0.00%0.00%0.00%0.00%0.00%CTTCCompetitive Technologies0.00%0.00%0.00%0.00%0.00%IONMAssure0.00%0.00%-39.33%+28,900.00%-99.44%SPDESpeedus0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/AN/AN/ACTTCCompetitive TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AIONMAssureN/AN/AN/AN/AN/AN/AN/AN/ASPDESpeedusN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADYXAlliqua BioMedical 0.00N/AN/AN/ACTTCCompetitive Technologies 0.00N/AN/AN/AIONMAssure 0.00N/AN/AN/ASPDESpeedus 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/ACTTCCompetitive TechnologiesN/AN/AN/AN/AN/AN/AIONMAssure$149K0.61N/AN/A($41.04) per share0.00SPDESpeedusN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADYXAlliqua BioMedicalN/AN/A0.00N/AN/AN/AN/AN/AN/ACTTCCompetitive TechnologiesN/AN/A0.00N/AN/AN/AN/AN/AN/AIONMAssure-$26.08MN/A0.00∞N/A-25,178.32%N/A-249.78%N/ASPDESpeedusN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADYXAlliqua BioMedicalN/AN/AN/AN/AN/ACTTCCompetitive TechnologiesN/AN/AN/AN/AN/AIONMAssureN/AN/AN/AN/AN/ASPDESpeedusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADYXAlliqua BioMedicalN/AN/AN/ACTTCCompetitive TechnologiesN/AN/AN/AIONMAssureN/A0.200.20SPDESpeedusN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADYXAlliqua BioMedicalN/ACTTCCompetitive TechnologiesN/AIONMAssure3.33%SPDESpeedusN/AInsider OwnershipCompanyInsider OwnershipADYXAlliqua BioMedical17.40%CTTCCompetitive Technologies17.50%IONMAssure3.80%SPDESpeedus48.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADYXAlliqua BioMedical6N/AN/ANot OptionableCTTCCompetitive Technologies7N/AN/ANot OptionableIONMAssure1303.13 million3.02 millionNot OptionableSPDESpeedus20N/AN/ANot OptionableSPDE, ADYX, IONM, and CTTC HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comMedia Sentiment Over TimeSPDE, ADYX, IONM, and CTTC Company DescriptionsAlliqua BioMedical OTCMKTS:ADYXAdynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.Competitive Technologies OTCMKTS:CTTCCalmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.Assure NASDAQ:IONM$0.03 0.00 (0.00%) As of 07/8/2025Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. It offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures. The company delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing services to support surgeons and medical facilities during invasive procedures. Assure Holdings Corp. is based in Englewood, Colorado.Speedus OTCMKTS:SPDESpeedus Corp., through its subsidiaries, engages in the development of diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists, and other healthcare professionals in the United States. The company offers computer-aided medical devices and telemedicine based delivery systems, including Zargis Cardioscan device, a non-invasive diagnostic support solution that automatically analyzes acoustical data from a patient to determine whether or not the patient possesses a suspected diastolic or systolic murmur; ZargisTelemed portal; and Signal X6 device, which records heart and lung sounds from six adhesive acoustic sensors. It also develops and markets ultra-high speed storage systems comprising JetX10 acceleration appliance, JetPod, and JetNode expansion chassis for server networks and other applications. In addition, the company offers local multipoint distribution service license, an FCC commercial operating license, which covers between 150300 MHz of spectrum in the New York City area. Further, it holds investments in a portfolio of marketable securities and in equity and debt instruments of non-publicly held companies. The company was formerly known as SPEEDUS.COM, Inc. and changed its name to Speedus Corp. in May 2002. Speedus Corp. was founded in 1995 and is based in Freehold, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
